'Bev ox ct' diaporamas de présentation

Integration of EGFR targeting into first line therapy: is it time?

Integration of EGFR targeting into first line therapy: is it time?. Prof Eric Van Cutsem, MD, PhD Leuven, Belgium. The Epidermal Growth Factor Receptor pathway. Scaltriti M & Baselga J. Clin Cancer Research 2006. Anti-EGFR antibodies in mCRC. cetuximab + irinotecan (n=218).

558 views • 32 slides

Introduction

341 views • 21 slides

Introduction

An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for 1 st ?line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE).

290 views • 20 slides